相似文献
1
Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: Safety considerations of impurities in pharmaceutical products and surveying the impurity landscape.
AAPS PharmSciTech. 2014 Feb;15(1):237-51. doi: 10.1208/s12249-013-0061-z. Epub 2013 Dec 21.
2
Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms.
AAPS PharmSciTech. 2014 Feb;15(1):198-212. doi: 10.1208/s12249-013-0047-x. Epub 2013 Nov 27.
3
Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
Int J Pharm. 2020 Feb 25;576:119018. doi: 10.1016/j.ijpharm.2019.119018. Epub 2020 Jan 3.
4
Identification of an Adduct Impurity of an Active Pharmaceutical Ingredient and a Leachable in an Ophthalmic Drug Product Using LC-QTOF.
J Pharm Sci. 2019 Oct;108(10):3187-3193. doi: 10.1016/j.xphs.2019.06.009. Epub 2019 Jun 18.
5
Forced degradation and impurity profiling: recent trends in analytical perspectives.
J Pharm Biomed Anal. 2013 Dec;86:11-35. doi: 10.1016/j.jpba.2013.07.013. Epub 2013 Jul 31.
6
Overview of genotoxic impurities in pharmaceutical development.
Int J Toxicol. 2009 Nov-Dec;28(6):468-78. doi: 10.1177/1091581809349195.
7
Elemental impurities in pharmaceutical products adding fuel to the fire.
Regul Toxicol Pharmacol. 2019 Nov;108:104435. doi: 10.1016/j.yrtph.2019.104435. Epub 2019 Jul 31.
8
A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
Regul Toxicol Pharmacol. 2023 Mar;139:105355. doi: 10.1016/j.yrtph.2023.105355. Epub 2023 Feb 13.
9
A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials.
J Pharm Biomed Anal. 2006 Jun 16;41(4):1251-9. doi: 10.1016/j.jpba.2006.03.013. Epub 2006 Apr 18.
10
Selective determination of potential impurities in an active pharmaceutical ingredient using HPLC-SPE-HPLC.
J Pharm Biomed Anal. 2013 Oct;84:41-7. doi: 10.1016/j.jpba.2013.05.033. Epub 2013 Jun 13.
引用本文的文献
1
Identification and Structural Characterization of Degradation Products of Linagliptin by Mass Spectrometry Techniques.
Int J Mol Sci. 2024 Feb 23;25(5):2591. doi: 10.3390/ijms25052591.
2
Photostability of Topical Agents Applied to the Skin: A Review.
Pharmaceutics. 2019 Dec 20;12(1):10. doi: 10.3390/pharmaceutics12010010.
3
An overview of cephalosporin antibiotics as emerging contaminants: a serious environmental concern.
3 Biotech. 2019 Jun;9(6):231. doi: 10.1007/s13205-019-1766-9. Epub 2019 May 24.
4
Neurobehavioral Effects of Cephalosporins: Assessment of Locomotors Activity, Motor and Sensory Development in Zebrafish.
Front Pharmacol. 2018 Mar 2;9:160. doi: 10.3389/fphar.2018.00160. eCollection 2018.
5
Informing Efforts to Develop Nitroreductase for Amine Production.
Molecules. 2018 Jan 24;23(2):211. doi: 10.3390/molecules23020211.
6
Embryo and Developmental Toxicity of Cefazolin Sodium Impurities in Zebrafish.
Front Pharmacol. 2017 Jun 26;8:403. doi: 10.3389/fphar.2017.00403. eCollection 2017.
7
Methodological assessment of the reduction of the content of impurities in nimodipine emulsion via the use of 21 amino acid protection.
Int J Nanomedicine. 2017 Apr 27;12:3407-3419. doi: 10.2147/IJN.S130348. eCollection 2017.
8
Consequences of New Approach to Chemical Stability Tests to Active Pharmaceutical Ingredients.
Front Pharmacol. 2016 Feb 8;7:17. doi: 10.3389/fphar.2016.00017. eCollection 2016.
本文引用的文献
1
Implications of in-use photostability: proposed guidance for photostability testing and labeling to support the administration of photosensitive pharmaceutical products, part 1: drug products administered by injection.
J Pharm Sci. 2013 Nov;102(11):3888-99. doi: 10.1002/jps.23717. Epub 2013 Sep 5.
2
Direct evidence of 2-cyano-2-propoxy radical activity during AIBN-based oxidative stress testing in acetonitrile-water solvent systems.
J Pharm Sci. 2013 May;102(5):1554-68. doi: 10.1002/jps.23500. Epub 2013 Mar 11.
3
Implementing quality by design in pharmaceutical salt selection: a modeling approach to understanding disproportionation.
Pharm Res. 2013 Jan;30(1):203-17. doi: 10.1007/s11095-012-0863-9. Epub 2012 Aug 24.
4
Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
Regul Toxicol Pharmacol. 2012 Jul;63(2):298-312. doi: 10.1016/j.yrtph.2012.03.016. Epub 2012 Apr 7.
5
Recent trends in the impurity profile of pharmaceuticals.
J Adv Pharm Technol Res. 2010 Jul;1(3):302-10. doi: 10.4103/0110-5558.72422.
6
Impact of metal-induced degradation on the determination of pharmaceutical compound purity and a strategy for mitigation.
J Pharm Biomed Anal. 2011 Apr 5;54(5):987-94. doi: 10.1016/j.jpba.2010.11.035. Epub 2010 Nov 30.
7
Artifactual formylation of the secondary amine of duloxetine hydrochloride by acetonitrile in the presence of titanium dioxide: implications for HPLC method development.
J Pharm Biomed Anal. 2010 Nov 2;53(3):432-9. doi: 10.1016/j.jpba.2010.05.007. Epub 2010 May 12.
8
Identification and control of metal-chelating chromatographic artifacts in the analysis of a malonohydrazide derivative drug compound.
J Pharm Biomed Anal. 2010 Nov 2;53(3):371-5. doi: 10.1016/j.jpba.2010.04.021. Epub 2010 Apr 24.
9
Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.
J Pharm Biomed Anal. 2010 Aug 1;52(4):493-507. doi: 10.1016/j.jpba.2010.01.043. Epub 2010 Feb 2.
10
A critical assessment of the ICH guideline on photostability testing of new drug substances and products (Q1B): Recommendation for revision.
J Pharm Sci. 2010 Jul;99(7):2934-40. doi: 10.1002/jps.22076.
Zotero 插件